LATER

Closed

ANZ 0501: LATER

BCT Study Chair:

John Forbes

The LATER trial addresses the important question of whether additional treatment with the aromatase inhibitor letrozole, commenced much later, for example from five to 15 years after the initial diagnosis of breast cancer, could reduce the risk of breast cancer returning in this large and high risk group of women.

0

INTERNATIONAL

Total number of trial

participants internationally

360

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

30

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

LATER TRANSLATIONAL RESEARCH SAMPLES

Randomised trial of letrozole plus usual care versus usual care without letrozole to prevent new breast cancer events in postmenopausal women who have completed a minimum of 4 years of adjuvant endocrine therapy for early hormone responsive breast cancer more than 1 year previous and who are disease free at trial entry (ACTRN12607000137493)

LATER PUBLICATIONS

2016

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.

Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Mann GB, Coates AS, Gebski V, Davies L, Thornton R, Reaby L, Cuzick J, Green M, on behalf of the Australia and New Zealand Breast Cancer Trials Group. Annals of Oncology. 2016; epub 20 March 2016 E-pub

2015

Final analysis of a randomized comparison of letrozole (Let) vs observation (Obs) as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive (HR+) breast cancer (BC) after completion of prior AET: ANZBCTG 0501 (LATER).

Zdenkowski N, Green M, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Gebski V, Veillard A-S, Davies LC, Thornton R, Fong A, Reaby LL, Forbes JF. Journal of Clinical Oncology 2015; 33(suppl; abstr 514), Abstract

2010

ANZ 0501 Later adjuvant Aromatase inhibitor Therapy for postmenopausal women with Endocrine Responsive breast cancer (LATER).

Thornton R, Hunter LM, Ward A, Boyle F, Green M, Forbes JF. COSA 2010; Poster 243, Poster

Clinical Trials Open for Participant Entry.

Forbes JF, Boyle F, Wilcken N, Lindsay DF, Leong E. COSA 2010; Poster 242, Poster

LATER